Gilead Sciences Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Gilead Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View analyst ratings for Gilead Sciences or view top-rated stocks.

13 analysts have issued 12-month price targets for Gilead Sciences' shares. Their GILD stock forecasts range from $56.00 to $90.00. On average, they expect Gilead Sciences' share price to reach $72.07 in the next year. This suggests a possible upside of 16.6% from the stock's current price.
View analysts' price targets for Gilead Sciences or view top-rated stocks among Wall Street analysts.

Gilead Sciences' stock was trading at $72.61 on January 1st, 2022. Since then, GILD shares have decreased by 14.9% and is now trading at $61.81.
View the best growth stocks for 2022 here.

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Gilead Sciences.

Gilead Sciences, Inc. (NASDAQ:GILD) posted its quarterly earnings data on Thursday, April, 28th. The biopharmaceutical company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.35. The biopharmaceutical company earned $6.59 billion during the quarter, compared to the consensus estimate of $6.28 billion. Gilead Sciences had a trailing twelve-month return on equity of 44.98% and a net margin of 16.43%. The company's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period last year, the company earned $2.08 EPS.
View Gilead Sciences' earnings history.

Gilead Sciences declared a quarterly dividend on Monday, May 2nd. Investors of record on Wednesday, June 15th will be given a dividend of $0.73 per share on Wednesday, June 29th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.72%. The ex-dividend date of this dividend is Tuesday, June 14th.
View Gilead Sciences' dividend history.

Gilead Sciences(NASDAQ:GILD) pays an annual dividend of $2.92 per share and currently has a dividend yield of 4.69%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Gilead Sciences has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Gilead Sciences is 81.56%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 46.65% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences' dividend history.

Gilead Sciences updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of $6.20-$6.70 for the period, compared to the consensus estimate of $6.50. The company issued revenue guidance of $23.80 billion-$24.30 billion, compared to the consensus revenue estimate of $24.48 billion.

107 employees have rated Gilead Sciences CEO Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among Gilead Sciences' employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO) and Ionis Pharmaceuticals (IONS).
View all of GILD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GILD stock can currently be purchased for approximately $61.81.

Gilead Sciences (NASDAQ:GILD) has a market capitalization of $77.53 billion and generates $27.31 billion in revenue each year. The biopharmaceutical company earns $6.23 billion in net income (profit) each year or $3.579990 on an earnings per share basis.

Gilead Sciences employs 14,400 workers across the globe.

Gilead Sciences was founded in 1987.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The official website for Gilead Sciences is www.gilead.com. The biopharmaceutical company can be reached via phone at (650) 574-3000, via email at [email protected], or via fax at 650-578-9264.